A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
10/1999
10/14/1999	WO1999051630A1 Lipopeptides inducing t lymphocytic cytotoxicity bearing at least one auxiliary t epitope, and uses for vaccination
10/14/1999	WO1999051629A2 New compounds for dna-transfection
10/14/1999	WO1999051581A1 Novel nucleic acid transfer agents, compositions containing same and uses
10/14/1999	WO1999051278A1 Inorganic material for radioactive drug delivery
10/14/1999	WO1999051273A1 Gelling ophthalmic compositions containing xanthan gum
10/14/1999	WO1999051272A1 Injectable igf-formulations containing succinate as buffering agent
10/14/1999	WO1999051271A2 Compositions comprising glycol derivatives and alcohols
10/14/1999	WO1999051270A1 A novel nitroreductase and therapeutic uses therefor
10/14/1999	WO1999051265A1 Nucleic acid encoding hyaluronan synthase and methods of use
10/14/1999	WO1999051239A1 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
10/14/1999	WO1999051230A1 Method for stabilizing pharmaceutical compositions by special use of an antioxidant
10/14/1999	WO1999051221A1 Hydrolytically unstable biocompatible polymer
10/14/1999	WO1999051212A2 Device for the transdermal delivery of diclofenac
10/14/1999	WO1999051210A1 Modified starch coating
10/14/1999	WO1999051208A1 Controlled release composition
10/14/1999	WO1999051206A1 Cationic lipid formulation delivering nucleic acid to peritoneal tumors
10/14/1999	WO1999051204A1 Ocular irrigating solution
10/14/1999	WO1999051202A2 Quinolone containing liposomes and their use as antibacterial agents
10/14/1999	WO1999051174A1 Steam-generating pad
10/14/1999	WO1999043361A8 Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
10/14/1999	WO1999043311A3 Conjugated suramin or derivatives thereof with peg, polyaspartate or polyglutamate for cancer treatment
10/14/1999	WO1999037275A3 COSMETIC OR PHARMACEUTICAL PREPARATIONS WITH A LESS STICKY FEEL, CONTAINING GLYCERIN ESTERS OF α-HYDROXY CARBOXYLIC ACIDS AND SATURED FATTY ACIDS
10/14/1999	WO1999036090A9 Oral delivery of nucleic acid vaccines by particulate complexes
10/14/1999	WO1999026660A3 Conjugates of cytokines and drugs or genes for treating proliferating cells
10/14/1999	DE19817517A1 New benzylguanidine derivatives useful for diagnosis or therapy, especially of neuroblastoma
10/14/1999	DE19816070A1 Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden Release tablet made of linear water-insoluble polysaccharides
10/14/1999	DE19814087A1 Feuchtigkeitsaktivierbares therapeutisches System Moisture-activatable therapeutic system
10/14/1999	DE19814083A1 Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen A process for the production of transdermal therapeutic systems using basic alkali metal salts for the conversion of active substance salts into the free bases
10/14/1999	DE19813011A1 Verfahren zur Herstellung von Mikrokapseln A process for the preparation of microcapsules
10/14/1999	DE19813010A1 Mikrokapseln mit verzögertem Release Microcapsules with delayed release
10/14/1999	CA2740948A1 Antibody variants and fragments thereof
10/14/1999	CA2328294A1 Lipopeptides inducing t lymphocytic cytotoxicity bearing at least one auxiliary t epitope, and uses for vaccination
10/14/1999	CA2327367A1 New compounds for dna-transfection
10/14/1999	CA2326977A1 Inorganic material for radioactive drug delivery
10/14/1999	CA2326497A1 Liposome composition and method for administering a quinolone
10/14/1999	CA2326183A1 Modified starch coating
10/14/1999	CA2326130A1 Cationic lipid formulation delivering nucleic acid to peritoneal tumors
10/14/1999	CA2325849A1 Pentaerythritol lipid derivatives
10/14/1999	CA2325400A1 Device for the transdermal delivery of diclofenac
10/14/1999	CA2325342A1 Dual avb3 and metastasis-associated receptor ligands
10/14/1999	CA2325050A1 A novel nitroreductase and therapeutic uses therefor
10/14/1999	CA2324931A1 Novel nucleic acid transfer agents, compositions containing same and uses
10/14/1999	CA2228822A1 A polypeptide vector for the delivery of immunogenic epitopes to the immune system using an injection, orally, by a nasal spray, skin patch or transplantable instruments
10/13/1999	EP0948965A1 Stable medicinal compositions containing 4,5-epoxymorphinane derivatives
10/13/1999	EP0948963A1 Pig appeasing pheromones to decrease stress, anxiety and aggressiveness
10/13/1999	EP0948957A2 Use of copolymers of monoethylenically unsaturated carboxylic acids as solubiliser
10/13/1999	EP0948638A1 Method for preparing compositions for transferring nucleic acids
10/13/1999	EP0948600A2 Nanoscale particles synthesized within an assembled virion
10/13/1999	EP0948544A1 Monovalent antibody fragments
10/13/1999	EP0948510A1 Immunostimulatory nucleic acid molecules
10/13/1999	EP0948363A1 Extremely flexible plaster acting dermally or transdermally, and method for producing same
10/13/1999	EP0948360A1 Novel lipid compounds and compositions containing same used for the transfer of at least an active substance, in particular a polynucleotide, in a target cell and therapeutic use
10/13/1999	EP0948359A1 Compositions containing lipophilic oligosaccharide antibiotic and albumin
10/13/1999	EP0948358A1 Stable liquid interferon formulations
10/13/1999	EP0948357A1 Use of low molecular weight amino alcohols in ophthalmic compositions
10/13/1999	EP0948341A1 Phospholipid drug derivatives
10/13/1999	EP0948340A1 Biologically active substances, method for obtaining and compositions containing them
10/13/1999	EP0948337A1 Treatment of hemoglobin containing erythrocytes with nitric oxide
10/13/1999	EP0948336A1 Palatable hydroxypropyl methylcellulose ether powder with specified particle size
10/13/1999	EP0948329A1 Use of green porphyrins for the manufacture of a medicament for the treatment of secondary cataracts
10/13/1999	EP0948321A2 Preparation in form of a matrix material-auxiliary agent compound containing optionally an active substance
10/13/1999	EP0948320A1 PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF THE HMG-CoA REDUCTASE INHIBITOR FLUVASTATIN
10/13/1999	EP0948319A2 Encapsulated cells producing antibodies
10/13/1999	EP0948318A1 Granulates comprising a water soluble compound and cellulose
10/13/1999	EP0920467A4 Hydrophilic and hydrophobic polyether polyurethanes and uses therefor
10/13/1999	EP0715637B1 Silicone grafted thermoplastic elastomeric copolymers and hair and skin care compositions containing the same
10/13/1999	EP0658111B1 Methods for enhancing drug delivery with modified saponins
10/13/1999	EP0588869B1 X-ray contrast agent
10/13/1999	CN1231700A Loxoprofen-containing preparation for external use
10/13/1999	CN1231609A Antimycotic gel with active substance release
10/13/1999	CN1231606A Composition comprising mupirocin and chlorhexidine
10/13/1999	CN1231603A Dosage form providing a sustained and ascending drug release
10/13/1999	CN1231601A Oral delayed immediate release formulation and method of preparation therefor
10/13/1999	CN1231600A Oral preparation containing at least one active pharmaceutical substance in a matrix capable of swelling in an aqueous medium
10/13/1999	CN1231593A Fatty acid esters of lactic acid salts as permeation enhancers
10/13/1999	CN1231592A Fatty acid esters of glycolic and its salts as permeation enhancers
10/13/1999	CN1231582A Use of bilayer forming emulsifiers in nutritional compositions comprising divalent metal salts
10/13/1999	CN1231299A Use of copolymers of monoethylenically unsaturated carboxylic acids as solubilizers
10/13/1999	CN1045621C Process for preparing immunoglobulin conjugates
10/12/1999	US5965721 With improved nuclease resistance and improved cellular uptake; for antisense agents and regulation of rna expression
10/12/1999	US5965714 Method for the covalent attachment of polysaccharides to protein molecules
10/12/1999	US5965695 Modified peptide and peptide libraries with protease resistance, derivatives thereof and methods of producing and screening such
10/12/1999	US5965603 Nonaqueous compositions for parenteral administration
10/12/1999	US5965566 High molecular weight polymer-based prodrugs
10/12/1999	US5965549 Ciprofloxacin-hydrocortisone suspension
10/12/1999	US5965528 Inhibiting the proliferation of autoreactive immune cells in a mammal by administering unglycosylated recombinant human alpha-fetoprotein produced by a prokaryotic cell; treating autoimmune diseases such as multiple sclerosis
10/12/1999	US5965519 Covalent polar lipid conjugates with biologically-active compounds for use in salves
10/12/1999	US5965404 Adding nucleic acid/polycation complexes to animal cells in presence of ethylene glycol and/or glycerol; for simple and accurate transfection of cells for gene therapy and tumor vaccine production
10/12/1999	US5965383 Fibrin binding domain polypeptides and uses and methods of producing same
10/12/1999	US5965168 Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
10/12/1999	US5965167 Composition containing microspheres produced by imposing liquiflash on active agent and processing aid and coating of blend of polymers having different levels of hydrophilicity; sustained release
10/12/1999	US5965166 Dry shearing a mixture of 60-95% acetaminophen and a direct compression vehicle, microcrystalline cellulose, into a stable homogenous granulate; mixing with a lubricant and compressing into a solid dose
10/12/1999	US5965161 Extruded multi-particulates
10/12/1999	US5965158 Liposomal-polyene preliposomal powder and method for its preparation
10/12/1999	US5965156 Amphotericin B liposome preparation
10/12/1999	US5965152 Controlled release of miotic and mydriatic drugs in the anterior chamber
10/12/1999	US5965133 Self-assembling multimeric nucleic acid constructs
10/12/1999	US5965132 Methods and compositions for targeting the vasculature of solid tumors
10/12/1999	US5965131 Galactosylated clearing agent binds to the primary binding site of the primary targeting species, and only non-bound primary targeting species is cleared, not bound species second site is not blocked by the clearing agent
10/12/1999	US5965125 Hybrid matrix implants and explants

1 ... 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 1429 1430 ... 1712